Skip to main content

Table 3 Survival of patients grouped by the VTS score

From: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

VTS score n = 110 median OS (months) logrank pairwise
0–1 46 5.1 vs. 1.5: 0.001
vs. 2: 0.0001
1.5 36 18.9 vs. 2: 0.03
2 28 34.5  
  1. Abbreviations: VTS Volume-timing-systemic therapy, OS Overall survival